Cowen analyst Charles Ryhee lowered the firm’s price target on Amwell to $5 from $9 and keeps an Outperform rating on the shares. The analyst said we believe 2023 guidance is built on conservative assumptions with minimal CVS, which could lead to potential upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMWL: